NDAORALCAPSULEPriority Review
Approved
Sep 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MILONTIN (phensuximide) is an oral succinimide anticonvulsant approved in 1953 for the treatment of absence seizures. It works by suppressing the paroxysmal 3 Hz spike-and-wave discharges characteristic of absence epilepsy, though its precise mechanism of action at the molecular level remains incompletely characterized. This legacy small-molecule therapy remains a treatment option for patients with generalized absence seizures.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal linked job volume, MILONTIN teams are likely small, focused on maintenance and compliance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MILONTIN offers limited growth potential due to zero linked job openings and approaching loss of exclusivity; this is a maintenance-focused assignment best suited for professionals with legacy product expertise or those seeking to stabilize a niche therapeutic area. Career trajectory on this product is likely lateral or defensive rather than accelerating.
Regulatory Affairs Specialist
Worked on MILONTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.